Multiple Endocrine Neoplasia malady

Genetics Home Reference: Multiple endocrine neoplasia is part of a group of disorders that affect the body's network of hormone-producing glands (the endocrine system). Hormones are chemical messengers that travel through the bloodstream and regulate the function of cells and tissues throughout the body. Multiple endocrine neoplasia involves tumors in at least two endocrine glands; tumors can also develop in other organs and tissues. These growths can be noncancerous (benign) or cancerous (malignant). If the tumors become cancerous, some cases can be life-threatening.¹⁷

MalaCards: Multiple Endocrine Neoplasia, also known as adenomatosis, familial endocrine, is related to multiple endocrine neoplasia type 2a and familial medullary thyroid carcinoma. An important gene associated with Multiple Endocrine Neoplasia is RET (ret proto-oncogene), and among its related pathways are Development_GDNF family signaling and Development GDNF family signaling. The compounds phosphatidylinositol and glucose have been mentioned in the context of this disorder. Affiliated tissues include small intestine, colon and adipocyte, and related mouse phenotypes are respiratory system and endocrine/exocrine gland.

Wikipedia: The term multiple endocrine neoplasia (MEN) encompasses several distinct syndromes featuring tumors of...⁴⁴ more...

multiple endocrine neoplasia 17 8 32 43 adenomatosis, familial endocrine 17 familial endocrine adenomatosis 17 malignant neoplasm of thyroid 43 endocrine neoplasia, multiple 17

endocrine gland neoplasms 43 thyroid cancer 17 adenomatosis 43 men 17 mea 17

Diseases related to multiple endocrine neoplasia by text searches and GeneDecks gene sharing:

(show top 50)    (show all 901)

id	Related Disease	Score	Top Affiliating Genes
1	multiple endocrine neoplasia type 2a	40.1	RET, VHL, ANXA5, CALCA, NF1, SHC1
2	familial medullary thyroid carcinoma	37.0	RET, CALCA, GDNF
3	hirschsprung's disease	36.7	RET, VIP, NRTN, GFRA1, PSPN, NPY
4	wermer syndrome	35.5	SF1, GCG, ZFPL1, CHGA, JUND, CDC73
5	primary hyperparathyroidism	35.4	RET, PBX1, SCT, CHGA, CDC73, MEN1
6	zollinger-ellison syndrome	35.3	SCT, CHGA, CDH1, MEN1, GHRH, SST
7	alcoholism	34.9	SCT, GHRH, GHRL, SP1, CRH, NF2
8	familial isolated hyperparathyroidism	33.8	RET, CDC73, MEN1, CASR, PTH, GAST
9	neuroendocrine tumor	33.5	RET, GCG, VIP, SDHD, SCT, CHGB
10	cushing's syndrome	33.4	GH1, SST, CRH, POMC
11	endocrine gland cancer	33.1	RET, GCG, VIP, CHGA, IGFBP3, GNAS
12	thyroid cancer	33.1	RET, APC, CALCA, PPARG, TG, NME1
13	carney complex	32.8	CNC, VHL, CHGA, CDKN1B, MEN1, GNAS
14	gastrinoma	32.8	GCG, VIP, SCT, CHGA, CDKN2A, INS
15	hypogonadism	32.7	PBX1, INS, IGFBP3, IGF1, GNRH1, CALCA
16	hyperparathyroidism	32.5	RET, VIP, BRCA2, PBX1, SDHB, SDHC
17	thyroid medullary carcinoma	32.3	RET, BRCA1, CHGA, CDH2, CALCA, SST
18	von hippel-lindau disease	32.2	RET, CNC, VIP, BRCA1, BRCA2, VHL
19	ganglioneuroma	32.0	RET, VIP, VHL, CHGA, PTEN, DLK1
20	somatotrophinoma	31.8	CDKN2A, MEN1, APC, IGF1, GNAS, GH1
21	goiter	31.8	RET, VHL, INS, IGFBP3, IGF1, GNAS
22	angiofibroma	31.7	CDH2, CDH1, MEN1, APC, CTNNB1, ACTC1
23	pituitary tumor	31.6	CNC, VIP, PBX1, CHGB, CHGA, CDKN1B
24	neuroma	31.5	RET, VHL, CALCA, SST, NF1, NF2
25	parathyroid carcinoma	31.5	CDC73, MEN1, CASR, PTH
26	duodenal gastrinoma	31.4	SCT, MEN1, GAST
27	vipoma	31.3	VIP, SCT, CHGA, MEN1, CALCA, GH1
28	insulinoma	31.3	GCG, VIP, BRCA1, PBX1, SDHB, SDHD
29	thyroid cancer, follicular	31.2	CDKN1A, CALCA, PTEN, PPARG, TG
30	pancreatic gastrinoma	31.1	PPP2R5B, PDX1, GAST
31	thyroid carcinoma	31.1	RET, BRCA1, BRCA2, VHL, UBC, JUN
32	was-related disorders	30.9	CHGA, CDC73, CDKN1C, INS, MEN1, IGF1
33	pheochromocytoma	30.9	RET, VIP, VHL, SDHB, SDHC, SDHD
34	coronary heart disease	30.9	GCG, CDKN2B, CDKN2A, INS, FGF2, MBL2
35	constipation	30.8	RET, VIP, CHGA, PTEN, SST, NRTN
36	carcinoid syndrome	30.8	VIP, CHGA, MEN1, IGF1, CALCA, GHRH
37	cowden disease	30.7	RET, CNC, BRCA1, BRCA2, AKT2, PTEN
38	gigantism	30.7	CDKN2B, CDKN2A, CDKN1C, INS, MEN1, IGFBP3
39	hypogonadotropism	30.6	INS, GNRH1, GHRH, GHRL, SST, CRH
40	hyperparathyroidism-jaw tumor syndrome	30.6	RET, CDC73, MEN1, CASR
41	adrenal adenoma	30.5	VHL, SDHB, SDHC, SDHD, CHGA, CDKN1C
42	atrophic gastritis	30.5	SCT, CHGA, MEN1, GHRL, DLK1, GAST
43	medullary sponge kidney	30.4	RET, INS, GDNF
44	papillary thyroid carcinoma	30.4	RET, CDH1, MEN1, APC, CALCA, PTEN
45	acromegaly	30.3	CNC, GCG, VIP, PBX1, CHGA, CDKN1B
46	adrenocortical carcinoma	30.2	VIP, CHGA, CDKN1C, IGF1R, CRH, POMC
47	peutz-jeghers syndrome	30.1	CNC, BRCA2, VHL, UBC, APC, AKT2
48	duodenitis	30.1	GCG, VIP, SCT, CHGA, CDKN2A, CDH1
49	end stage renal failure	30.1	INS, MEN1, IGF1, PTH, PRL, EPO
50	androgenetic alopecia	30.0	INS, SRD5A1, CTNNB1, PRL

Approved drugs:

Drug clinical trials:

MalaCards organs/tissues related to multiple endocrine neoplasia:

²²

MGI Mouse Phenotypes related to multiple endocrine neoplasia:

²⁵ (show all 28)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	respiratory system phenotype	MP:0005388	10.2	RET, BRCA1, CDC73, CDKN2D, AMHR2, CALCA
2	endocrine/exocrine gland phenotype	MP:0005379	9.8	REG1A, RET, SF1, BRCA1, BRCA2, CDKN2C
3	liver/biliary system phenotype	MP:0005370	9.5	VHL, PBX1, JUND, CDC73, INS, MEN1
4	craniofacial phenotype	MP:0005382	9.2	PBX1, CDKN1C, MEN1, GRB2, MAPK8, MAPK9
5	limbs/digits/tail phenotype	MP:0005371	9.1	RET, BRCA1, BRCA2, VHL, PBX1, CDKN1C
6	embryogenesis phenotype	MP:0005380	9.0	RET, BRCA1, BRCA2, VHL, PBX1, SDHD
7	pigmentation phenotype	MP:0001186	9.0	BRCA1, CDKN1B, CDKN2A, APC, CASR, PTEN
8	immune system phenotype	MP:0005387	8.3	BRCA1, BRCA2, PBX1, JUND, CDKN2C, CDC73
9	reproductive system phenotype	MP:0005389	8.3	REG1A, RET, SF1, VIP, BRCA1, BRCA2
10	renal/urinary system phenotype	MP:0005367	8.0	RET, BRCA1, VHL, PBX1, CHGA, CDKN1A
11	hematopoietic system phenotype	MP:0005397	8.0	BRCA1, BRCA2, VHL, JUND, CDKN1A, CDKN2C
12	no phenotypic analysis	MP:0003012	8.0	RET, CDKN1B, CDH1, INS, APC, MAP4K2
13	normal phenotype	MP:0002873	8.0	RET, VIP, BRCA1, BRCA2, VHL, PBX1
14	hearing/vestibular/ear phenotype	MP:0005377	7.3	PBX1, UCN, CDKN1A, CDKN2D, CDKN1B, FGF2
15	integument phenotype	MP:0010771	7.3	BRCA1, BRCA2, VHL, PBX1, CDKN1A, CDKN2C
16	adipose tissue phenotype	MP:0005375	6.7	BRCA1, CDKN1A, CDC73, CDKN1B, INS, APC
17	nervous system phenotype	MP:0003631	6.7	BRCA1, PBX1, SDHD, SCT, CHGB, UCN
18	behavior/neurological phenotype	MP:0005386	6.3	VIP, BRCA2, PBX1, SCT, UCN, JUN
19	digestive/alimentary phenotype	MP:0005381	6.1	RET, GCG, BRCA1, BRCA2, VHL, PBX1
20	mortality/aging	MP:0010768	5.9	RET, SF1, GCG, BRCA1, BRCA2, VHL
21	vision/eye phenotype	MP:0005391	5.9	JUN, CDKN1A, CDKN2D, CDKN1B, CDKN2A, CDKN1C
22	muscle phenotype	MP:0005369	5.7	RET, BRCA1, VHL, JUND, CDKN1A, CDH2
23	skeleton phenotype	MP:0005390	5.3	BRCA1, BRCA2, VHL, PBX1, JUN, CDKN1A
24	tumorigenesis	MP:0002006	5.3	RET, SF1, BRCA1, BRCA2, VHL, SDHD
25	growth/size phenotype	MP:0005378	4.7	RET, GCG, BRCA1, BRCA2, VHL, PBX1
26	cardiovascular system phenotype	MP:0005385	4.7	RET, BRCA1, VHL, PBX1, SDHD, CHGA
27	cellular phenotype	MP:0005384	3.0	RET, BRCA1, BRCA2, VHL, PBX1, SDHD
28	homeostasis/metabolism phenotype	MP:0005376	2.0	REG1A, RET, SF1, GCG, VIP, BRCA1

Articles related to multiple endocrine neoplasia:

(show top 50)    (show all 428)

id	Title	Authors	Year	Affiliating Genes
1	Bilateral adrenocortical carcinoma in a patient with multiple endocrine neoplasia type 1 (MEN1) and a novel mutation in the MEN1 gen e. (21266030)	Griniatsos J.E.... Kaltsas G.	2011	MEN1
2	Multiple endocrine neoplasia type 1-associated cystic pancreatic endocrine neoplasia and multifocal cholesterol granulomas. (20403035)	Kimura N.... Ishizaka M.	2010	MEN1, REG1A
3	Modification of multiple endocrine neoplasia 2A phenotype by cell membrane proximity of RET mutations in exon 10. (18936155)	Machens A.... Dralle H.	2008	RET
4	Proteomic profiling of von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B. (17639059)	Brouwers F.M.... Zhuang Z.	2007	CHGB
5	MEN1 mutation analysis in Chinese patients with multiple endocrine neoplasia type 1. (18045958)	Jiang X.H.... Ning G.	2007	MEN1
6	Carcinogenic hypergastrinemia: signet-ring cell carcinoma in a patient with multiple endocrine neoplasia type 1 with Zollinger-Ellison's syndrome. (17609302)	Schott M.... Scherbaum W.A.	2007	CDH1, GAST
7	Broad tumor spectrum in a mouse model of multiple endocrine neoplasia type 1. (17044021)	Loffler K.A.... Kay G.F.	2007	MEN1
8	Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas. (17179192)	Perren A.... Kloppel G.	2007	MEN1
9	DelD631: a novel mutation of the RET proto-oncogene in multiple endocrine neoplasia type 2A (MEN2A) (17923033)	Yao B.... Weng J.P.	2007	RET
10	Two novel mutations in the MEN1 gene in subjects with multiple endocrine neoplasia-1. (16840830)	Ozturk M.... Jap T.S.	2006	MEN1
11	Presymptomatic thyroidectomy in multiple endocrine neoplasia 2a. (16325365)	Heizmann O.... Oertli D.	2006	CALCA
12	Cost analysis of DNA-based testing in a large Canadian family with multiple endocrine neoplasia type 2. (15355438)	Gilchrist D.M.... Brown J.L.	2004	RET
13	Pancreatic beta-cell-specific ablation of the multiple endocrine neoplasia type 1 (MEN1) gene causes full penetrance of insulinoma development in mice. (12941803)	Bertolino P.... Wang Z.Q.	2003	MEN1
14	Molecular diagnosis of multiple endocrine neoplasia T ype 2. (14628904)	Bugalho M.J.... Sobrinho L.	2003	RET
15	Diagnostic and therapeutic approach to multiple endocrine neoplasia type 2B in pediatric patients. (12415360)	Torre M.... Jasonni V.	2002	RET
16	Pituitary adenomas in adolescent patients with multiple endocrine neoplasia type 1. (12625413)	Oiwa A.... Hashizume K.	2002	PRL, GH1
17	Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers. (11900218)	Sanso G.E.... Barontini M.	2002	RET
18	Molecular genetic diagnostic program of multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma syndromes in Hungary. (11524247)	Klein I.... VA!radi A.	2001	RET
19	Multiple endocrine neoplasia type 2 syndromes may be associated with renal malformations. (11454140)	LorAc F.... Renieri A.	2001	RET
20	Germline mutation of the RET proto-oncogene in members of Slovak families with multiple endocrine neoplasia 2. (11949835)	Poturnajova M.... Altaner C.	2001	RET
21	Identification of three novel menin mutations (c.741delGTCA, c.1348T>C, c.1785delA) in unrelated Italian families affected with multiple endocrine neoplasia type 1: additional information for mutational screening. (11241849)	Asteria C.... Beck-Peccoz P.	2001	MEN1
22	From gene to disease; from the RET gene to multiple endocrine neoplasia types 2A and 2B, sporadic and familial medullary thyroid carcinoma, Hirschsprung disease and papillary thyroid carcinoma (11757244)	Hofstra R.M.... Lips C.J.	2001	RET
23	Novel deletional mutation of the MEN 1 gene in a kind red with multiple endocrine neoplasia type 1. (10945663)	Kakizawa T.... Hashizume K.	2000	MEN1
24	Multiple endocrine neoplasia type 2A. Study of a family. (10731788)	Correia M.J.... Tuna J.L.	2000	RET
25	Association of medullary sponge kidney disease and multiple endocrine neoplasia type IIA due to RET gene mutation: is there a causal relationship? (11096158)	Diouf B.... Diop T.M.	2000	RET
26	Intestinal ganglioneuromatosis and multiple endocrine neoplasia type 2B: implications for treatment. (10369718)	Smith V.V.... Milla P.J.	1999	RET, CALCA
27	Comparative genomic hybridization studies in tumours from a patient with multiple endocrine neoplasia type 1. (9724078)	KytAPlAo S.... Salmela P.	1998	MEN1
28	Expression of the MEN-1 gene in a large kindred with multiple endocrine neoplasia type 1. (9681844)	Burgess J.R.... Shepherd J.J.	1998	MEN1
29	Exclusion of the phosphoinositide-specific phospholipase C beta 3 (PLCB3) gene as a candidate for multiple endocrine neoplasia type 1. (9003510)	Weber G.... Larsson C.	1997	PLCB3, MEN1
30	A kindred with a variant of multiple endocrine neoplasia type 1 demonstrating frequent expression of pituitary tumors but not linked to the multiple endocrine neoplasia type 1 locus at chromosome region 11q13. (9024241)	Stock J.L.... Aronin N.	1997	IGFBP3
31	The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck. (9393871)	Bocciardi R.... Rossi B.	1997	RET, GRB2, CRK
32	Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. (9360560)	Gimm O.... Eng C.	1997	RET
33	Localization of the multiple endocrine neoplasia type I (MEN1) gene based on tumor loss of heterozygosity analysis. (9157974)	Emmert-Buck M.R.... Debelenko L.V.	1997	PYGM
34	Management of patients and subjects at risk for multiple endocrine neoplasia type 1: MEN 1. GENEM 1. Groupe d'Etude des NAcoplasies Endocriniennes Multiples de type 1. (9167954)	Chanson P.... Murat A.	1997	PBX1, SCT
35	Ligand stimulation of a Ret chimeric receptor carryin g the activating mutation responsible for the multiple endocrine neoplasia type 2B. (8910618)	Rizzo C.... de Franciscis V.	1996	RET
36	Somatotrophinomas in multiple endocrine neoplasia type 1: a review of clinical phenotype and insulin-like growth factor-1 levels in a large multiple endocrine neoplasia type 1 kindred. (8644767)	Burgess J.R.... Greenaway T.M.	1996	IGF1
37	Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. (8626834)	Frank-Raue K.... Ziegler R.	1996	RET
38	Gs alpha mutation may be uncommon in patients with multiple endocrine neoplasia type 1. (8964883)	Sakurai A.... Hashizume K.	1996	GNAS
39	Diagnosis and management of pheochromocytomas in patients with multiple endocrine neoplasia type 2-relevance of specific mutations in the RET proto-oncogene. (8810737)	Frank-Raue K.... Raue F.	1996	RET
40	Genetic mapping studies of 40 loci and 23 cosmids in chromosome 11p13-11q13, and exclusion of mu-calpain as the multiple endocrine neoplasia type 1 gene. (8641689)	Pang J.T.... Thakker R.V.	1996	CAPN1
41	Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2. (8675600)	Pausova Z.... Hendy G.N.	1996	RET
42	Clinical use of molecular information in the management of multiple endocrine neoplasia type 2A. (7595169)	Gagel R.F.... Schultz P.N.	1995	RET
43	Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. (7532281)	Asai N.... Takahashi M.	1995	RET
44	Prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1. (7491542)	MacFarlane M.P.... Jensen R.T.	1995	GAST
45	Point mutation within the tyrosine kinase domain of the RET proto- oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. (7911697)	Eng C.... Ponder B.A.J.	1994	RET
46	Parent-of-origin effects in multiple endocrine neoplasia type 2B. (7977365)	Carlson K.M.... Goodfellow P.J.	1994	RET
47	Current perspectives on the diagnosis and management of patients with multiple endocrine neoplasia type 2 syndromes. (7913027)	Wells S.A.... Donis-Keller H.	1994	RET
48	Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. (8099202)	Mulligan L.M.... Ponder B.A.J.	1993	RET
49	Multiple endocrine neoplasia II A syndrome: relationship between age of the patient, levels of basal calcitonin and size of the thyroid tumor (1352395)	Parrilla P.... Rodriguez J.M.	1992	CALCA
50	A case of multiple endocrine neoplasia: hyperparathyroidism, insulinoma, GRF-oma, hypercalcitoninaemia and intractable peptic ulceration. (1356665)	Price D.E.... Howlett T.A.	1992	GAST

Genes related to multiple endocrine neoplasia according to GeneCards:

(show top 50)    (show all 134)

id	Symbol	Description	Score	GeneCards Section Context
1	RET	ret proto-oncogene	11.1	Summaries, Publications, Aliases & Descriptions
2	MEN1	multiple endocrine neoplasia I	11.1	Summaries, Transcripts, Publications, Orthologs (show all 6 sections) Aliases & Descriptions, Functions
3	DNAJC4	DnaJ (Hsp40) homolog, subfamily C, member 4	11.1	Aliases & Descriptions
4	DPF2	D4, zinc and double PHD fingers family 2	11.1	Publications, Summaries
5	CDKN1B	cyclin-dependent kinase inhibitor 1B (p27, Kip1)	11.0	Publications
6	VHL	von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase	11.0	Publications
7	NF1	neurofibromin 1	11.0	Publications
8	CNC	Carney complex, multiple neoplasia and lentiginosis	11.0	Publications
9	GAST	gastrin	11.0	Publications
10	PLCB3	phospholipase C, beta 3 (phosphatidylinositol-specific)	11.0	Publications
11	CHGA	chromogranin A (parathyroid secretory protein 1)	11.0	Publications
12	SDHD	succinate dehydrogenase complex, subunit D, integral membrane protein	11.0	Publications
13	SDHC	succinate dehydrogenase complex, subunit C, integral membrane protein, 15kDa	11.0	Publications
14	CALCA	calcitonin-related polypeptide alpha	11.0	Publications
15	PRKAR1A	protein kinase, cAMP-dependent, regulatory, type I, alpha	11.0	Publications
16	GDNF	glial cell derived neurotrophic factor	11.0	Publications
17	GNAS	GNAS complex locus	11.0	Publications
18	SDHB	succinate dehydrogenase complex, subunit B, iron sulfur (Ip)	11.0	Publications
19	CDC73	cell division cycle 73, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae)	11.0
20	RNF11	ring finger protein 11	11.0	Summaries
21	GFRA4	GDNF family receptor alpha 4	11.0	Publications
22	PNMT	phenylethanolamine N-methyltransferase	11.0	Publications
23	SF1	splicing factor 1	11.0	Publications
24	PYGM	phosphorylase, glycogen, muscle	11.0	Publications
25	CHGB	chromogranin B (secretogranin 1)	11.0	Publications
26	GHRHR	growth hormone releasing hormone receptor	11.0	Publications
27	SCT	secretin	11.0	Publications
28	JUND	jun D proto-oncogene	11.0	Publications
29	PTH	parathyroid hormone	11.0	Publications
30	GFRA1	GDNF family receptor alpha 1	11.0	Publications
31	MAPK7	mitogen-activated protein kinase 7	11.0
32	GHRH	growth hormone releasing hormone	11.0	Publications
33	ACTC1	actin, alpha, cardiac muscle 1	11.0	Publications
34	MAPK9	mitogen-activated protein kinase 9	11.0	Publications
35	NUDT6	nudix (nucleoside diphosphate linked moiety X)-type motif 6	11.0	Publications
36	TFF1	trefoil factor 1	11.0	Publications
37	SLC6A2	solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2	11.0	Publications
38	GHRL	ghrelin/obestatin prepropeptide	11.0	Publications
39	SRD5A1	steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1)	11.0
40	PRL	prolactin	11.0	Publications
41	SST	somatostatin	11.0	Publications
42	SHC1	SHC (Src homology 2 domain containing) transforming protein 1	11.0	Publications
43	ANXA5	annexin A5	11.0	Publications
44	TH	tyrosine hydroxylase	11.0	Publications
45	VIP	vasoactive intestinal peptide	11.0	Publications
46	NF2	neurofibromin 2 (merlin)	11.0
47	CASR	calcium-sensing receptor	11.0	Publications
48	SMAD3	SMAD family member 3	11.0
49	BRCA2	breast cancer 2, early onset	11.0
50	TG	thyroglobulin	11.0	Publications

Pathways related to multiple endocrine neoplasia according to GeneDecks:

(show top 50)    (show all 194)

id	Pathway	Score	Top Affiliating Genes
1	Development_GDNF family signaling41	10.6	GRB2, MAPK9, AKT2, GDNF, PSPN, GFRA4
2	Development GDNF family signaling10	10.6	GFRA1, SHC1, NRTN, AKT2, MAPK9, PSPN
3	Class B/2 (Secretin family receptors)38	10.6	CALCA, GNAS, GHRH, GHRHR, PTH, CRH
4	Signal transduction_PTEN pathway41	10.6	IGF1R
5	Development Ligand-independent activation of ESR1 and ESR210	10.5	GRB2, GNAS, AKT2, SHC1, TFF1, PRKAR1A
6	Development_Ligand-independent activation of ESR1 and ESR241	10.3	GNAS, AKT2, SHC1, TFF1, PRKAR1A, IGF1
7	GDNF-Family Ligands and Receptor Interactions36	10.1	GFRA1, JUN, MAPK9, NRTN, GFRA4, PSPN
8	Breast Cancer Regulation by Stathmin136	10.1	NUDT6, PLCB3, FGF2, GRB2, MAPK7, IGF1R
9	Immune response Oncostatin M signaling via MAPK in human cells10	10.0	SHC1, MAPK9, GRB2, MAPK8, JUND, EGR1
10	Immune response_MIF-JAB1 signaling41	9.8	MAPK9, MAPK8, GRB2, CDK4, CDKN1B, JUN
11	Development Role of Activin A in cell differentiation and proliferation10	9.7	GNAS, CDKN1B, CDKN2B, CDKN1A, PRKAR1A, SMAD3
12	Development_Role of Activin A in cell differentiation and proliferation41	9.7	SP1, SMAD3, PRKAR1A, CDKN1B, GNAS, CDKN2B
13	Transcription Receptor-mediated HIF regulation10	9.6	IGFBP3, IGF1, AKT2, SHC1, GRB2, INS
14	Development_Endothelin-1/EDNRA signaling41	9.6	CTNNB1, SHC1, AKT2, GNAS, MAPK9, MAPK8
15	Signal transduction_JNK pathway41	9.5	MAP4K2, MAPK8, MAPK9, JUND, CRK, JUN
16	JNK Pathway36	9.5	JUN, GHRH, FGF2, GRB2, ANGPTL1, MAPK8
17	Transcription_Receptor-mediated HIF regulation41	9.5	IGFBP3, SHC1, PTEN, IGF1, AKT2, GRB2
18	Development_FGFR signaling pathway41	9.5	CRK, GRB2, SHC1, FGF2, JUN, UBC
19	Development FGFR signaling pathway10	9.5	AKT2, CRK, MAPK9, MAPK8, GRB2, JUN
20	Immune response_Oncostatin M signaling via MAPK in human cells41	9.4	EGR1, JUN, SHC1, PPARG, MAPK9, MAPK8
21	Ras Pathway36	9.3	FGF2, JUN, GRB2, MAPK9, EPOR, NUDT6
22	TGF-beta Signaling Pathways37	9.3	JUND, JUN, GRB2, MAPK8, MAPK9, SHC1
23	Development Endothelin-1/EDNRA signaling10	9.3	AKT2, SHC1, PLCB3, CTNNB1, GNAS, MAPK8
24	Development_HGF signaling pathway41	9.3	SHC1, CRK, CTNNB1, JUN, AKT2, MAPK9
25	Glioblastoma Multiforme36	9.2	APC, GRB2, CDK4, CDKN1A, CDKN1B, IGF1R
26	Chronic myeloid leukemia20	9.1	CRK, SMAD3, AKT2, GRB2, CDK4, CDKN1B
27	ErbB signaling pathway20	9.0	CDKN1B, SHC1, AKT2, MAPK9, JUN, CRK
28	G1-S Phase Transition36	9.0	CDKN2B, CDKN1B, CDKN2D, CDKN2C, CDKN1A, CDK4
29	Cyclins and Cell Cycle Regulation36	9.0	CDKN2C, PPP2R5B, CDKN2B, CDKN2D, CDKN2A, CDKN1B
30	Cell cycle Regulation of G1/S transition (part 1)10	8.9	BRCA1, CDKN1A, SMAD3, PPP2R5B, SP1, CDK4
31	14-3-3 Induced Intracellular Signaling36	8.9	EPOR, PLCB3, GHRH, GH1, GNRH1, IGF1
32	GPCR Pathway36	8.8	IGF1R, EPOR, PRKAR1A, PLCB3, MAPK8, CRK
33	TGF-Beta Pathway36	8.8	JUN, FGF2, GRB2, ANGPTL1, MAPK8, IGF1
34	Cell cycle_Regulation of G1/S transition (part 1)41	8.8	BRCA1, UBC, SMAD3, CDKN2A, PPP2R5B, SP1
35	NFAT in Immune Response36	8.8	GH1, MAPK9, EPOR, NUDT6, GHRH, JUN
36	p70S6K Signaling36	8.8	INS, GHRH, GH1, GNRH1, IGF1R, MAPK7
37	MAPK Family Pathway36	8.8	JUN, FGF2, GRB2, ANGPTL1, MAPK8, MAP4K2
38	Renin-Angiotensin Pathway36	8.7	GRB2, FGF2, GNRH1, JUN, NUDT6, IGF1R
39	Glioma20	8.5	SHC1, PTEN, AKT2, IGF1, CDKN2A, CDK4
40	Signal transduction PTEN pathway10	8.5	JUN, SHC1, CTNNB1, PTEN, AKT2, CDKN1A
41	GSK3 Signaling36	8.4	MAPK8, APC, MAPK7, CTNNB1, PPP2R5B, GHRH
42	Prostate cancer20	8.4	CTNNB1, PTEN, AKT2, IGF1R, GRB2, INS
43	Estrogen Pathway36	8.4	MAPK9, IGF1R, EPOR, MAPK8, GRB2, FGF2
44	MAPK Signaling36	8.3	IGF1R, MAPK7, MAPK9, MAPK8, GRB2, FGF2
45	Melanoma20	8.1	PTEN, AKT2, IGF1, IGF1R, FGF2, CDH1
46	ILK Signaling36	8.0	JUND, GH1, CDH1, MAPK9, EPOR, IGF1R
47	Pancreatic Adenocarcinoma36	7.7	FGF2, GH1, CDKN2A, EPOR, NUDT6, GHRH
48	Pathways in cancer20	7.6	JUN, CDKN1A, CDKN2B, CDKN1B, PTEN, BRCA2
49	JAK-STAT Pathway36	7.5	UBC, EPO, NUDT6, PRL, SP1, GHRH
50	Molecular Mechanisms of Cancer36	6.2	CDKN2A, CDK4, CDH1, FGF2, CDKN1B, CDKN2B

Compounds related to multiple endocrine neoplasia according to GeneDecks:

(show top 50)    (show all 352)

id	Compound	Score	Top Affiliating Genes
1	phosphatidylinositol32	11.0	RET, BRCA2, VHL, CDKN1B, MAPK9, MAPK7
2	glucose32	9.9	GCG, VHL, SCT, UCN, CDK4, APC
3	estradiol32 9 18 9	12.6	BRCA1, BRCA2, PBX1, CDKN1B, CDK4, GRB2
4	hexarelin32	9.5	PBX1, IGFBP3, IGF1, GH1, GHRH, GHRHR
5	rapamycin32 42	10.5	GCG, VHL, CDK4, INS, MAPK8, MAP4K2
6	clonidine32 9 9	11.3	SCT, CHGA, FGF2, IGFBP3, IGF1, CALCA
7	h2o232	9.2	VIP, BRCA1, BRCA2, SDHB, JUND, GRB2
8	epinephrine32 9 18 9	12.2	GCG, VIP, SDHB, SCT, CHGA, INS
9	ly29400232	9.1	RET, GCG, VHL, JUN, CDKN1B, CDH1
10	5-hydroxytryptamine32	9.1	GCG, VIP, CHGA, FGF2, GNRH1, CALCA
11	nitric oxide32 9 18 9	12.1	VHL, CHGA, UCN, CDKN1B, CDKN2A, CDK4
12	arginine32	9.0	RET, GCG, VIP, PBX1, SDHB, SCT
13	forskolin32 42 9 9	11.9	GCG, VIP, SCT, CHGA, UCN, JUN
14	norepinephrine32 9 18 9	11.9	GCG, VIP, SDHB, SCT, CHGB, CHGA
15	calcium32 9 18 9	11.8	REG1A, VIP, BRCA1, VHL, SDHB, SCT
16	dopamine32 9 18 9	11.8	RET, GCG, VIP, SDHB, SCT, CHGB
17	cyclic amp32 18	9.8	RET, CNC, GCG, PBX1, SCT, CHGA
18	gnrh32	8.7	GCG, PBX1, INS, IGFBP3, IGF1, GNAS
19	ribonucleic acid32	8.7	RET, CHGA, UCN, IGF1R, IGFBP3, IGF1
20	pge232	8.6	VIP, SCT, CDH1, FGF2, APC, IGF1R
21	acetylcholine32 9 18 9	11.5	GCG, VIP, SCT, CHGA, UCN, IGF1R
22	dihydrotestosterone32 9 18 9	11.4	VIP, CDKN1B, CDK4, CDH1, FGF2, IGF1R
23	doxorubicin32 34 9 9	11.4	BRCA1, CDKN1B, CDK4, CDH1, ANXA5, MAPK9
24	ibmx32	8.2	GCG, VIP, SCT, INS, FGF2, IGF1R
25	adenylate32	8.1	GCG, VIP, SCT, CHGA, UCN, CDH2
26	agar32	8.0	RET, BRCA1, CDKN1B, CDKN2A, CDK4, CDH1
27	glutamate32	8.0	GCG, VIP, SDHB, JUND, CDH2, CDKN1B
28	thyroxine32 18	9.0	VIP, SCT, INS, FGF2, MBL2, IGFBP3
29	octreotide32 42 9 9	10.8	GCG, VIP, SCT, CHGA, INS, IGF1R
30	cysteine32	7.6	GCG, BRCA1, SDHB, SCT, CDH2, CDKN2A
31	creatinine32	7.3	GCG, SDHB, CHGA, CDKN2A, CDH1, MBL2
32	calcitriol32 42 9 18 9	11.3	JUN, CDKN1A, CDKN1B, CDK4, CDH1, FGF2
33	resveratrol32 9 18 9	10.3	BRCA1, BRCA2, JUN, CDKN1A, CDKN1B, CDK4
34	lipid32	7.2	RET, GCG, BRCA1, PBX1, SDHB, SCT
35	testosterone32 9 18 9	10.2	RET, VIP, BRCA1, BRCA2, PBX1, SDHB
36	alanine32	7.0	RET, GCG, VIP, BRCA1, CDKN1B, CDKN2A
37	estrogen32	6.8	GCG, VIP, BRCA1, BRCA2, VHL, CHGB
38	butyrate32	6.8	RET, GCG, JUN, CDKN1A, CDKN1B, CDKN2A
39	actinomycin d32	6.8	VHL, JUN, CDKN1A, CDKN1B, CDKN2A, FGF2
40	pd 98,05932	6.7	RET, GCG, SCT, JUN, JUND, CDKN1A
41	wortmannin32 42	7.7	RET, GCG, JUN, CDKN1A, CDKN1B, CDH1
42	sb 20358032 42	7.5	GCG, JUN, JUND, CDKN1A, CDKN1B, CDK4
43	tamoxifen32 34 9 9	9.5	BRCA1, BRCA2, CHGA, JUN, CDKN1A, CDKN1B
44	paraffin32	6.3	RET, BRCA1, BRCA2, CHGA, CDKN1A, CDH2
45	vitamin d32	6.1	CHGA, JUN, CDKN1A, CDK4, CDH1, MEN1
46	thymidine32 18	7.0	REG1A, VIP, BRCA1, BRCA2, SCT, JUN
47	cisplatin32 34 9 9	8.9	BRCA1, BRCA2, CHGA, JUND, CDKN1A, CDKN1B
48	genistein32 9 18 9	8.3	REG1A, RET, GCG, BRCA1, BRCA2, JUN
49	retinoic acid32 42 18	7.1	RET, BRCA1, BRCA2, SDHC, SCT, CHGA
50	dexamethasone32 42 34 9 9	8.7	VIP, PBX1, CHGB, CHGA, UCN, UBC

Cellular components related to multiple endocrine neoplasia according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	mitochondrial respiratory chain complex II	GO:005749	10.2	SDHB, SDHD, SDHC
2	secretory granule	GO:030141	9.9	GHRL, GHRHR, INS, CHGA, CHGB, BRCA2
3	extracellular space	GO:005615	7.9	DLK1, SST, CRH, TFF1, NPY, POMC
4	extracellular region	GO:005576	7.4	GNRH1, REG1A, PTH, SST, SPINK5, PPY
5	cytoplasm	GO:005737	7.0	POMC, CDC42EP2, CDKN2A, CDKN1B, CDKN2D, CDKN2B
6	nucleoplasm	GO:005654	6.9	JUN, SP1, HNRNPA3, SMAD1, MAPK7, MAPK9
7	cytosol	GO:005829	5.7	NME1, SMAD3, SMAD1, SNX15, NRP1, PPARG
8	nucleus	GO:005634	4.6	NME1, PPARG, CTNNB1, SP1, PTEN, AIP

Biological processes related to multiple endocrine neoplasia according to GeneDecks:

(show all 43)

id	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of growth hormone secretion	GO:060124	10.8	GHRH, GHRHR, GHRL
2	osteoblast fate commitment	GO:002051	10.7	SMAD5, SMAD1, MEN1
3	induction of apoptosis by hormones	GO:008628	10.7	CRH, PTH, SST
4	positive regulation of cAMP biosynthetic process	GO:030819	10.6	PTH, GHRHR, GHRH, CALCA, GCG
5	growth hormone secretion	GO:030252	10.6	GHRL, GHRH, GHRHR
6	monoamine transport	GO:015844	10.5	SLC18A2, SLC6A2, SLC18A1
7	MAPK cascade	GO:000165	10.5	NRTN, NF1, MEN1, RET, INS, SHC1
8	positive regulation of multicellular organism growth	GO:040018	10.4	GHRL, GHRHR, GHRH, GH1
9	neuron projection development	GO:031175	10.3	GDNF, SHC1, UCN, CDH1, NPY, NRTN
10	positive regulation of insulin-like growth factor receptor signaling pathway	GO:043568	10.3	IGF1, IGFBP3, GHRH, GH1, GHRHR
11	liver development	GO:001889	10.3	SP1, JUN, SRD5A1, SMAD3, PDX1, NF1
12	positive regulation of glycogen biosynthetic process	GO:045725	10.3	PTH, IGF1, INS, AKT2
13	positive regulation of osteoblast differentiation	GO:045669	10.2	FGF2, MEN1, IGF1, SMAD1, SMAD5, JUND
14	G-protein coupled receptor signaling pathway	GO:007186	10.2	CASR, GAST, UCN, PLCB3, SST, INS
15	positive regulation of glucose import	GO:046326	10.1	PTH, AKT2, IGF1, INS
16	nerve growth factor receptor signaling pathway	GO:048011	10.0	MAPK7, PTEN, CRK, SHC1, PRKAR1A, GRB2
17	transforming growth factor beta receptor signaling pathway	GO:007179	10.0	STUB1, SMAD3, SMAD1, SP1, MEN1, CDKN2B
18	fibroblast growth factor receptor signaling pathway	GO:008543	10.0	SHC1, UBC, CDKN1B, FGF2, GRB2, PTEN
19	regulation of angiogenesis	GO:045765	10.0	FGF2, NF1, MAPK7, CTNNB1
20	cellular response to indole-3-methanol	GO:071681	9.8	BRCA1, CDH1, CTNNB1
21	stress-activated MAPK cascade	GO:051403	9.8	MAPK7, MAPK9, JUN, MAPK8, UBC
22	cell-cell signaling	GO:007267	9.8	POMC, NRP1, SST, PTH, GHRH, CALCA
23	cellular response to organic cyclic compound	GO:071407	9.7	SRD5A1, SMAD1, SMAD5, CDKN1B, PPARG, CTNNB1
24	regulation of cyclin-dependent protein kinase activity	GO:000079	9.7	CDKN2C, PTEN, CDKN1B, CDKN1C, CDKN2D, CDKN2B
25	anti-apoptosis	GO:006916	9.6	IGF1R, EPO, VHL, GDNF, GHRL, GNRH1
26	aging	GO:007568	9.6	GRB2, JUN, SHC1, CALCA, EPO, SLC18A2
27	negative regulation of cyclin-dependent protein kinase activity	GO:045736	9.5	CDKN2A, CDKN1A, APC, MEN1, CDKN1B
28	positive regulation of DNA replication	GO:045740	9.4	JUN, INS, IGF1R, IGF1, EPO, UCN
29	negative regulation of phosphorylation	GO:042326	9.4	CDKN2C, CDKN2B, CDKN2D, CDKN1B, CDKN2A, CDKN1C
30	cell cycle arrest	GO:007050	9.3	CDKN1A, CDKN2C, CDKN2D, CDKN1B, CDKN2A, CDKN2B
31	G1 phase of mitotic cell cycle	GO:000080	9.1	CDK4, CDKN1C, CDKN2A, CDKN1B, CDKN2D, CDKN2C
32	insulin receptor signaling pathway	GO:008286	9.1	INS, FGF2, GRB2, IGF1R, AKT2, CRK
33	Ras protein signal transduction	GO:007265	8.9	CDKN2A, FGF2, GRB2, IGF1, SHC1, NF1
34	positive regulation of cell proliferation	GO:008284	8.9	GHRH, INS, FGF2, IGF1R, IGF1, CAPN1
35	response to estrogen stimulus	GO:043627	8.8	EPO, PPARG, BRCA1, GHRHR, GHRL
36	negative regulation of cell growth	GO:030308	8.5	CDKN1A, FGF2, PPARG, CDKN2C, CDKN2D, CDKN1B
37	negative regulation of apoptotic process	GO:043066	8.3	GCG, CDKN1A, CDKN1B, INS, EPO, NEUROD1
38	negative regulation of transcription, DNA-dependent	GO:045892	8.0	FGF2, CDKN2A, CTNNB1, CALCA, FOXN3, CDKN1C
39	response to drug	GO:042493	8.0	PPARG, CTNNB1, SRD5A1, SST, CDH1, CDK4
40	signal transduction	GO:007165	7.7	SMAD5, AIP, RET, GCG, CDK4, FGF2
41	positive regulation of transcription from RNA polymerase II promoter	GO:045944	7.4	JUN, BRCA1, UBC, MAPK7, JUND, CDC73
42	negative regulation of cell proliferation	GO:008285	7.3	IGFBP3, APC, IGF1, GNRH1, PTEN, SST
43	positive regulation of transcription, DNA-dependent	GO:045893	7.3	BRCA1, BRCA2, VHL, JUN, CDKN1C, CDH1

Molecular functions related to multiple endocrine neoplasia according to GeneDecks:

(show all 16)

id	Name	GO ID	Score	Top Affiliating Genes
1	monoamine transmembrane transporter activity	GO:008504	10.5	SLC18A2, SLC6A2, SLC18A1
2	transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity	GO:030618	10.4	SMAD5, SMAD3, SMAD1
3	G-protein coupled receptor binding	GO:001664	10.3	POMC, UCN, PPY, GHRL
4	RNA polymerase II core promoter sequence-specific DNA binding	GO:000979	10.2	SMAD1, SMAD5, MAZ, SP1
5	growth factor activity	GO:008083	9.9	NRTN, NUDT6, REG1A, FGF2, IGF1, GH1
6	neuropeptide hormone activity	GO:005184	9.9	NPY, VIP, UCN, CRH
7	R-SMAD binding	GO:070412	9.8	JUN, MEN1, CTNNB1, SMAD3
8	double-stranded DNA binding	GO:003690	9.7	NEUROG3, NEUROD1, POU3F4, EGR1, SMAD3, CTNNB1
9	receptor binding	GO:005102	9.6	GDNF, GCG, MBL2, NPY, POMC, PSPN
10	protein phosphatase binding	GO:019903	9.5	CDH2, CDKN1B, CDH1, GRB2, CTNNB1
11	protein kinase binding	GO:019901	9.4	CDKN2B, CDH2, CDKN2C, CDKN2D, CDKN2A, GRB2
12	transcription factor binding	GO:008134	9.2	MAPK9, AIP, SP1, PBX1, NEUROD1, CDKN2A
13	cyclin-dependent protein kinase inhibitor activity	GO:004861	9.2	CDKN2A, CDKN2C, CDKN1C, CDKN1B, CDKN2D, CDKN2B
14	hormone activity	GO:005179	9.0	GH1, PTH, SST, PPY, CRH, TG
15	transcription regulatory region DNA binding	GO:044212	9.0	BRCA1, PPARG, JUN, JUND, MEN1, SP1
16	protein binding	GO:005515	2.1	MAP4K2, RET, VPS51, BRCA1, BRCA2, VHL